CKLF1-C19 is the C-terminal peptide of human chemokine-like factor 1 (CKLF1). CKLF1-C19 interacts with CCR4 , and inhibits chemotaxis induced by both CKLF1 and CCL17 . CKLF1-C19 can suppress allergic lung inflammation via inhibiting chemotaxis mediated by CCR3 and CCR4 In Vitro CKLF1-C19 (200 ng/mL or 500 ng/mL; 30 min) induces chemotactic migration of human Th2 cells. CKLF1-C19 (100 ng/mL; 30 min) inhibits CCL11-induced chemotaxis of mouse eosinophils and human CCR3-transfected or mouse CCR3-transfected HEK293 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo CKLF1-C19 (0.01-100 μg, 200 μL; i.p.; single dose at day 24-26, 30 min before OVA induced) results in a significant reduction of airway hyperresponsiveness (AHR) compared to ovalbumin (OVA) group with saline . CKLF1-C19 (0.5 mg or 1 mg, 200 μL; s.c.; single dose) reduces CCL11-mediated recruitment of eosinophils into the peritoneal cavity in a mouse model of asthma . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:CCL17-CCR4 CCR3